 Home > Medical News > Latest Medical News > Nuocheng Jianhua won the Kunpeng Award of "2021 Best Original Small Molecule Chemical Drug TOP3 Enterprise"

Nuocheng Jianhua won the Kunpeng Award of "2021 Best Original Small Molecule Chemical Drug TOP3 Enterprise"

 Last Update: 2021-11-04
 Source: Internet
 Author: User

Tags

loperamide half life

rare rocks list

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Beijing, October 20, 2021/PRNewswire/ - The "2021 Nanjing International New Medicine and Life and Health Industry Innovation Investment Summit" hosted by the Nanjing Municipal Government released today the second "2021 China Biomedical Industry Chain Innovation Billboard"
.

Relying on the innovative abutinib and a series of innovative drug pipelines, Nuocheng Jianhua was named "2021 Best Original Research Small Molecule Chemical Drug TOP3 Enterprise" and won the "Kunpeng Award" in the 2021 China Biomedical Industry Chain Innovation List

The "2021 China Biomedical Industry Chain Innovation Billboard" is guided by the China Medical News Information Association and the China Biomedical Industry Chain Innovation and Transformation Alliance.
The editorial board of "Pharmaceutical Progress", Yaojiahui, Yaodu Jingwei, etc.
work together
.

The award judging panel includes academicians, clinicians, industry investors and market analysts, which is conducive to multi-perspective evaluation of the innovative value and market value of enterprises or new drugs.

Dr.
Cui Jisong, co-founder, chairman and CEO of Nuocheng Jianhua, said: “The biomedical industry is the strategic commanding heights of international technology and economic competition, and innovation is the first driving force for development
.

We are honored to be in this fertile land of Nanjing.

At present, Nuocheng Jianhua has independently developed a rich product pipeline in the two fields of malignant tumors and autoimmune diseases.
In addition to continuing to deepen the research and development of small molecule new drugs, it is also actively deploying large molecule new drug development
.

Since its establishment six years ago, the company has continuously increased its investment in innovative research and development and built a rich pipeline of innovative drugs

The 2021 Nanjing New Medicine and Life Health Innovation Investment Summit is a major event of the annual Nanjing Golden Autumn Economic and Trade Fair
.

With the theme of "delivering the frontier voices of new medicines, and gathering innovation and development momentum in'Ning'," this summit will carry out forward-looking, authoritative and predictive exchanges by building an internationally influential high-end exchange platform for new medicines and the life and health industry Dialogue and build an industrial ecology with multiple parties

About Nuocheng Jianhua

Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) is a commercialized biomedical high-tech company, focusing on the development of a class of new drugs in the treatment of malignant tumors and autoimmune diseases, suitable for the treatment of lymphoma and solid tumors And autoimmune diseases
.

Several new drug products are currently in commercialization, clinical and pre-clinical research and development stages

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.